^
Association details:
| Biomarker: | HER-2 positive |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) + brusatol (NRF2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Nrf2 Inhibitor, Brusatol in Combination with Trastuzumab Exerts Synergistic Antitumor Activity in HER2-Positive Cancers by Inhibiting Nrf2/HO-1 and HER2-AKT/ERK1/2 Pathways
Published date:
07/20/2020
Excerpt:
Therefore, we speculated that brusatol may have the potential to enhance trastuzumab efficacy in treating HER2-positive cancers. Results showed that the inhibitory effect of trastuzumab in combination with brusatol was significantly greater than that of either agent alone in both SK-OV-3 and BT-474 cancer cells, while the combinatorial treatment hardly shows superior activity compared to brusatol on SK-BR-3 cells (Figure 2(a)).
DOI:
https://doi.org/10.1155/2020/9867595
